209 related articles for article (PubMed ID: 23496667)
41. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
[TBL] [Abstract][Full Text] [Related]
42. The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).
Movahed F; Darzi S; Mahdavi P; Salih Mahdi M; Qutaiba B Allela O; Naji Sameer H; Adil M; Zarkhah H; Yasamineh S; Gholizadeh O
Virol J; 2024 May; 21(1):124. PubMed ID: 38822328
[TBL] [Abstract][Full Text] [Related]
43. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination.
Kaufmann AM; Nieland J; Schinz M; Nonn M; Gabelsberger J; Meissner H; Müller RT; Jochmus I; Gissmann L; Schneider A; Dürst M
Int J Cancer; 2001 Apr; 92(2):285-93. PubMed ID: 11291058
[TBL] [Abstract][Full Text] [Related]
44. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
[TBL] [Abstract][Full Text] [Related]
45. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.
Liao SJ; Deng DR; Zeng D; Zhang L; Hu XJ; Zhang WN; Li L; Jiang XF; Wang CY; Zhou JF; Wang SX; Zhang HW; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):735-742. PubMed ID: 24142729
[TBL] [Abstract][Full Text] [Related]
46. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells.
Luckau S; Wehrs TP; Brandau S; Horn PA; Lindemann M
J Immunother; 2016 Oct; 39(8):316-20. PubMed ID: 27548034
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer.
Wu TC
Eur J Immunol; 2007 Feb; 37(2):310-4. PubMed ID: 17273998
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic Vaccines Against Human Papilloma Viruses: Achievements and Prospects.
Vonsky MS; Runov AL; Gordeychuk IV; Isaguliants MG
Biochemistry (Mosc); 2019 Jul; 84(7):800-816. PubMed ID: 31509730
[TBL] [Abstract][Full Text] [Related]
49. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
50. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.
Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Lipetz C; Evans AS; Mason M
Vaccine; 2001 Mar; 19(17-19):2549-56. PubMed ID: 11257391
[TBL] [Abstract][Full Text] [Related]
51. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV
Dorta-Estremera S; Chin RL; Sierra G; Nicholas C; Yanamandra AV; Nookala SMK; Yang G; Singh S; Curran MA; Sastry KJ
Cancer Res; 2018 Sep; 78(18):5327-5339. PubMed ID: 30054333
[TBL] [Abstract][Full Text] [Related]
52. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.
Harper DM
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S11-7. PubMed ID: 18649932
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
Santin AD; Bellone S; Palmieri M; Zanolini A; Ravaggi A; Siegel ER; Roman JJ; Pecorelli S; Cannon MJ
J Virol; 2008 Feb; 82(4):1968-79. PubMed ID: 18057249
[TBL] [Abstract][Full Text] [Related]
54. Tertiary prevention of cervical cancer.
Divine LM; Huh WK
Clin Obstet Gynecol; 2014 Jun; 57(2):316-24. PubMed ID: 24633405
[TBL] [Abstract][Full Text] [Related]
55. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
Front Immunol; 2020; 11():188. PubMed ID: 32133000
[TBL] [Abstract][Full Text] [Related]
56. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
57. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
[TBL] [Abstract][Full Text] [Related]
58. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
Front Immunol; 2020; 11():927. PubMed ID: 32547541
[TBL] [Abstract][Full Text] [Related]
59. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
60. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
